Cencora, Inc. $COR Stock: Nisa Investment Advisors LLC Grows Stake

Nisa Investment Advisors LLC increased its stake in shares of Cencora, Inc. (NYSE:COR) by 13.3% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 91,364 shares of the company’s stock after acquiring an additional 10,723 shares during the period. Nisa Investment Advisors LLC’s holdings in Cencora were worth $27,432,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. BlackRock Inc. bought a new position in shares of Cencora in the 2nd quarter valued at approximately $5,154,136,000. Bank of America Corp DE lifted its holdings in Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after purchasing an additional 267,318 shares during the last quarter. Amundi boosted its position in Cencora by 43.5% during the second quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after purchasing an additional 676,066 shares during the period. Carmignac Gestion boosted its position in Cencora by 58.7% during the second quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after purchasing an additional 646,112 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Cencora during the second quarter worth approximately $483,772,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other news, EVP Elizabeth Campbell sold 11,300 shares of the business’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the transaction, the executive vice president owned 19,455 shares in the company, valued at approximately $6,305,754.60. The trade was a 36.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.38% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on COR shares. Argus increased their price target on Cencora from $340.00 to $380.00 and gave the company a “buy” rating in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Wells Fargo & Company boosted their price objective on shares of Cencora from $331.00 to $395.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. UBS Group decreased their price objective on shares of Cencora from $430.00 to $400.00 and set a “buy” rating for the company in a report on Friday. Finally, Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $366.31.

Cencora Trading Up 1.0%

Cencora stock opened at $343.39 on Wednesday. The company has a debt-to-equity ratio of 3.53, a quick ratio of 0.58 and a current ratio of 0.93. The business’s 50-day simple moving average is $320.90 and its 200-day simple moving average is $303.66. The firm has a market capitalization of $65.53 billion, a PE ratio of 19.83, a PEG ratio of 1.74 and a beta of 0.58. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $4.48 earnings per share for the quarter, topping the consensus estimate of $4.35 by $0.13. Cencora had a return on equity of 125.45% and a net margin of 0.79%. The business had revenue of $84.75 billion during the quarter, compared to analysts’ expectations of $84.31 billion. During the same quarter in the previous year, the firm earned $4.00 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. Equities research analysts forecast that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Friday, August 14th were paid a $0.60 dividend. The ex-dividend date was Friday, August 14th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 17.83%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Argus raised its price target for Cencora from $340 to $380 and assigned a “buy” rating. The new target implies approximately 10.7% upside from the recently cited share price, strengthening the bullish case for the pharmaceutical distributor. Cencora Inc. price target raised to $380 at Argus
• Positive Sentiment: Twenty-six exchange-traded funds added to their Cencora holdings on October 16, suggesting continued institutional interest and potentially providing support for the stock. 26 ETFs add to Cencora holdings
• Positive Sentiment: A separate stock analysis described Cencora as a robust healthcare company with an estimated 7.85% upside potential, reinforcing the view that its defensive healthcare distribution business remains attractive. Cencora stock analysis
• Neutral Sentiment: UBS lowered its price target to $400, a negative revision, but the target remains meaningfully above the recently cited share price and therefore still indicates potential upside. UBS cuts Cencora price target
• Neutral Sentiment: Pre-earnings coverage focused on Cencora’s valuation, with a price-to-earnings ratio near 25.4, while other reports simply tracked the stock ahead of quarterly results. These reports provide context but no new fundamental catalyst. Cencora valuation analysis

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical sourcing and distribution company. It provides branded, generic and specialty pharmaceuticals, over-the-counter products and related health care supplies to pharmacies, hospitals, health systems, physician practices and other health care providers.

The company also offers services to pharmaceutical and biotechnology manufacturers, including logistics, commercialization support, market access, consulting, clinical trial support and patient assistance programs.